Publications (135) Marta María Alonso Roldán publications

filter_list

2025

  1. Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial(Nature Medicine, 10.1038/s41591-023-02347-y)

    Nature Medicine

  2. Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors

    Molecular Cancer, Vol. 24, Núm. 1

  3. Correction: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

    Cancer Discovery

  4. Inhibition of T cell infiltration and soluble TNF signaling is neuroprotective in the alpha-synuclein overexpressing mouse model of Parkinson’s disease

    npj Parkinson's Disease, Vol. 11, Núm. 1

  5. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial

    Nature Medicine, Vol. 31, Núm. 3, pp. 861-868

  6. Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

    European Journal of Cancer, Vol. 217

  7. Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas

    Cell Reports Medicine, Vol. 6, Núm. 7

  8. The multilayered control of acetylation during adenovirus-based immunotherapy of cancer

    Molecular Therapy Oncology, Vol. 33, Núm. 2

  9. Toxicity and Biodistribution of the Oncolytic Virus VCN-01 Following Intracranial Injection in Syrian Hamsters

    Human Gene Therapy, Vol. 36, Núm. 17-18, pp. 1237-1247

  10. Translational advancement of immunotherapeutics against pediatric central nervous system tumors

    Advances in Cancer Research

  11. Virus Against Cancer: Paradigm-Shifting Biological Concepts

    Current Neurology and Neuroscience Reports, Vol. 25, Núm. 1

2024

  1. A road map for the treatment of pediatric diffuse midline glioma

    Cancer Cell

  2. Characterization of immune populations in the tumor microenvironment of diffuse midline glioma orthotopic mouse models by flow cytometry

    STAR Protocols, Vol. 5, Núm. 1

  3. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice

    Molecular Therapy, Vol. 32, Núm. 3, pp. 722-733

  4. Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models

    JCI Insight, Vol. 9, Núm. 18

  5. Differential Impact of Valproic Acid on SLC5A8, SLC12A2, SLC12A5, CDH1, and CDH2 Expression in Adult Glioblastoma Cells

    Biomedicines, Vol. 12, Núm. 7

  6. Evolution of invasive pneumococcal disease by serotype 3 in adults: a Spanish three-decade retrospective study

    The Lancet Regional Health - Europe, Vol. 41

  7. Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile

    Neuro-oncology, Vol. 26, Núm. 9, pp. 1723-1737

  8. Oncolytic adenoviruses and immunopeptidomics: a convenient marriage

    Molecular Oncology

  9. The emerging field of viroimmunotherapy for pediatric brain tumors

    Neuro-oncology, Vol. 26, Núm. 11, pp. 1981-1993